BioDelivery Initiates Phase I Study of Bioral Antifungal Drug
Posted on: Tuesday, 29 July 2008, 12:01 CDT
BioDelivery Sciences International has initiated its first Phase I clinical study assessing the safety, tolerability and pharmacokinetics of Bioral amphotericin B. This study is said to represent a significant step forward in the evaluation of BDSI's second drug delivery platform, known as Bioral.
BioDelivery Sciences International's (BDSI) Bioral drug delivery system appears to protect certain drugs from degradation in the gastrointestinal tract and facilitates their oral absorption through a novel process of encapsulation.
In the Phase I trial, the Bioral technology will be evaluated as a potential means of orally delivering the antifungal agent Amphotericin B, an important and well established treatment for serious fungal infections, which is currently administered only by intravenous injection.
Raphael Mannino, chief scientific officer of BDSI, said: "The ability to orally administer amphotericin B using the Bioral technology could have a major impact on treatment approaches for systemic fungal infections which often require hospitalization and intravenous therapy."
Source: Datamonitor
Related Articles
- Rodman & Renshaw Annual Global Investment Conference Presenter Profiles
- BioDelivery Sciences Initiates Bioral(R) Amphotericin B Clinical Program
- BDSI Exercises Option to Acquire U.S. BEMA(TM) Rights
- BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research
- BDSI Seeks OK of Oral Anti-Fungal Drug
- FDA Accepts BDSI Antifungal Drug for Review
- BDSI Announces FDA Acceptance of Bioral(R) Amphotericin IND
- Study Shows Bioral(R) Delivery Technology Delivers Influenza siRNA Therapeutic and Reduces Virus Levels By 200 Times in Mice
- BDSI Names Mark Sirgo As Chief Executive Officer
 |
 |
User Comments (0)
RSS Feeds